Anti-IgE therapy was proposed to two teenagers with cystic fibrosis (CF) with allergic bronchopulmonary aspergillosis (ABPA) exacerbation, reluctant to a further course of oral steroids. Both patients experienced ABPA exacerbations within the past 3 years, requiring oral steroid bursts. Clinical, laboratory and radiographic features were consistent with ABPA exacerbations (representing at the time of evaluation the fourth and third episodes for patient 1 and 2, respectively). Total serum IgE was very high, >1000 kU/litre in both cases. Treatment consisting of subcutaneous injections of 375 mg anti-IgE (omalizumab) twice monthly was successful in rapidly improving respiratory symptoms and lung function. Based on clinical and functional improvement, interval between injections was progressively increased and treatment could be withdrawn after 11 injections, without recurrence at 20 weeks of follow-up after withdrawal.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3029439 | PMC |
| http://dx.doi.org/10.1136/bcr.07.2008.0379 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Correlation of Sensitization with Mucus Plugging in COPD.
Int J Chron Obstruct Pulmon Dis
January 2025
Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, People's Republic of China.
Background: Both sensitization and mucus plugs are associated with poor clinical outcomes in COPD. However, little is known about the association between hypersensitivity and mucus plugging in patients with COPD.
Methods: We retrospectively enrolled COPD patients who had visited Peking University Third Hospital and received measurement of the specific IgE ( sIgE) from Oct 1, 2018 to Sep 30, 2023.
An immunological perspective in the treatment strategy of allergic bronchopulmonary aspergillosis.
QJM
January 2025
Flat 6 Souchay Court, 1 Clothorn Road, Manchester, M20 6BR.
Pulmonary overlap syndrome in a patient with bronchial asthma.
BMJ Case Rep
January 2025
Pulmonary, Critical Care and Sleep Medicine, ESICPGIMSR, New Delhi, Delhi, India.
Allergic bronchopulmonary aspergillosis (ABPA) is a disease of immunocompetent patients, and invasive pulmonary aspergillosis is seen in immunocompromised patients. Hence, pulmonary overlap syndrome presenting with ABPA and invasive aspergillosis is extremely rare. We report a case of well-controlled bronchial asthma who presented with acute exacerbation and hypoxaemic respiratory failure.
View Article and Find Full Text PDFRespiratory Outcomes and Aspergillus Serology Following Elexacaftor/Tezacaftor/Ivacaftor Therapy in People with Cystic Fibrosis and a History of Aspergillus fumigatus Infection.
Lung
January 2025
Mother and Child Department, Cystic Fibrosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Purpose: The study evaluated the effects of elexacaftor/tezacaftor/ivacaftor (ETI) therapy in people with cystic fibrosis (pwCF) and a clinical history of Aspergillus fumigatus (AF) infection.
Methods: This prospective cohort study included pwCF who initiated ETI therapy and had received antifungal treatment in the preceding five years due to allergic bronchopulmonary aspergillosis (ABPA group) or other AF-related clinical manifestations (AF group). A control group of pwCF with no prior respiratory cultures positive for AF was also included.
Unexpected radiological presentation in allergic bronchopulmonary aspergillosis: multiple lung masses.
Thorax
January 2025
Pneumology Department, Hospital Universitario San Cecilio, Granada, Spain.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!